Ovidac 10000 iu (HCG (Human Chorionic Gonadotropin))

Product Overview

Ovidac 10000 IU is a pharmaceutical formulation of Human Chorionic Gonadotropin (HCG) supplied by Bayer Zydus Pharma. Each package contains a single 1 ml vial of lyophilized powder intended for reconstitution with the accompanying 1 ml of sterile sodium chloride (NaCl) solution. The product is marketed for two primary therapeutic indications: female infertility and male hypogonadism. Pack sizes are available as 3 vials + 3 NaCl ampoules, 6 vials + 6 NaCl ampoules, or 9 vials + 9 NaCl ampoules, providing flexibility for clinical or research settings. The strength of each vial is 10,000 International Units (IU) of HCG, a dosage that has been extensively studied in assisted reproductive technology and endocrine research. Storage requires refrigeration at 2 °C to 8 °C prior to reconstitution, and the reconstituted solution should be used within a defined window to maintain potency.

What is Ovidac 10000 IU?

Human Chorionic Gonadotropin (HCG) is a glycoprotein hormone produced by the placenta during pregnancy. In clinical practice, recombinant or purified HCG is used to mimic the action of luteinizing hormone (LH) and follicle‑stimulating hormone (FSH) on the gonads. Ovidac 10,000 IU contains a standardized amount of this hormone that can be administered intramuscularly or subcutaneously after proper reconstitution. The hormone binds to LH receptors on ovarian cells, stimulating the production of androgens and ultimately promoting follicular maturation and ovulation. In males, HCG stimulates Leydig cells to produce testosterone, making it valuable for treating hypogonadotropic hypogonadism. The therapeutic profile of Ovidac aligns with the physiological actions described in peer‑reviewed literature on reproductive endocrinology (see NCBI Bookshelf for detailed mechanisms).

Uses and Benefits

Ovidac 10,000 IU is primarily prescribed to support ovulation induction in women undergoing controlled ovarian hyperstimulation for assisted reproductive techniques such as in‑vitro fertilization (IVF) and intrauterine insemination (IUI). By providing an exogenous LH surge, it triggers the final maturation of mature follicles, improving oocyte yield and pregnancy rates. In the context of male infertility, the same dosage can be employed to restore testosterone production in men with secondary hypogonadism, thereby enhancing spermatogenesis and sexual health. Beyond reproductive applications, HCG has been investigated for its ability to enhance athletic performance and muscle growth, although such uses fall outside approved medical indications and carry regulatory and ethical considerations. Clinicians value Ovidac for its consistent potency, long‑standing manufacturing pedigree, and the availability of multiple pack sizes that facilitate dose titration according to individual patient protocols.

How It Works

The pharmacodynamics of Ovidac 10,000 IU are rooted in its ability to activate the LH receptor on target cells, leading to downstream activation of cyclic AMP (cAMP) signaling pathways. In ovarian tissue, this results in increased production of androgens within granulosa cells, which are then aromatized to estradiol, creating a favorable hormonal environment for follicular development. The exogenous LH‑like activity also induces luteinization of the follicle after ovulation, supporting corpus luteum formation and progesterone secretion — both essential for endometrial receptivity. In males, HCG binding to Leydig cell LH receptors stimulates cholesterol side‑chain cleavage enzymes, boosting testosterone synthesis. This mechanism is well documented in clinical pharmacology references, including the FDA drug information page. The therapeutic effect is dose‑dependent, which is why precise reconstitution and accurate dosing are critical for achieving the desired hormonal response.

Dosage Guidelines

Dosage of Ovidac 10,000 IU must be individualized based on the clinical indication, patient age, body weight, and baseline hormonal levels. For ovulation induction in assisted reproduction, a typical regimen involves administering a single 10,000 IU dose intramuscularly or subcutaneously after ovarian stimulation with gonadotropins, followed by oocyte retrieval approximately 34–36 hours later. In male hypogonadism, the recommended protocol often consists of 1,500–2,500 IU administered two to three times per week for several weeks, with dose adjustments guided by serum testosterone measurements. Reconstitution requires gentle swirling of the vial with the supplied sterile 1 ml of 0.9 % NaCl solution; vigorous shaking can denature the protein and reduce activity. Once prepared, the solution should be used within 24 hours when stored at room temperature, or within 72 hours if kept refrigerated. Clinicians are advised to rotate injection sites to minimize tissue irritation and to monitor patients for adverse reactions throughout the treatment course.

Side Effects

Like all hormonal medications, Ovidac 10,000 IU can produce a spectrum of side effects ranging from mild to severe. Common adverse events include injection site reactions such as redness, swelling, or bruising, as well as mild abdominal discomfort and headache. More frequent hormonal side effects may comprise nausea, vomiting, breast tenderness, and mood fluctuations. Rare but clinically significant complications include ovarian hyperstimulation syndrome (OHSS) in women, characterized by rapid weight gain, shortness of breath, and reduced urine output, and the potential for thromboembolic events in predisposed individuals. In men, excessive testosterone conversion can lead to acne, increased libido, or polycythemia. Patients should be counseled to report any sudden weight gain, visual disturbances, or severe pelvic pain promptly. For a comprehensive list of reported reactions, clinicians may refer to the Drugs.com product page and the FDA safety communication.

Warnings and Precautions

Ovidac 10,000 IU is contraindicated in patients with known hypersensitivity to human chorionic gonadotropin or any component of the formulation, as well as in individuals with active or suspected malignant neoplasms, severe hepatic impairment, or uncontrolled endocrine disorders. Pregnant women should not receive HCG therapy, as exogenous hormone administration may interfere with natural pregnancy pathways and fetal development. Prior to initiation, a thorough medical history should be obtained to identify a history of thromboembolic disease, seizure disorders, or hormone‑sensitive tumors. Concomitant use of other gonadotropins or hormonal therapies requires careful monitoring to avoid supraphysiologic hormone levels. Laboratory monitoring, including serum estradiol, testosterone, and luteinizing hormone levels, is recommended at regular intervals to adjust dosing and mitigate the risk of overstimulation. Finally, proper disposal of unused vials and sharps must follow local biomedical waste regulations to ensure environmental safety.

Frequently Asked Questions

Question 1: How should Ovidac 10,000 IU be stored before use?
Answer: The lyophilized powder must be kept refrigerated at 2 °C–8 °C and protected from light. Once reconstituted with the supplied sterile NaCl solution, the vial can be stored at room temperature for up to 24 hours or refrigerated for up to 72 hours before administration.

Question 2: Can Ovidac be used for weight loss or bodybuilding?
Answer: Although HCG has been promoted for off‑label weight‑loss protocols, this use is not approved by regulatory agencies and lacks robust clinical evidence. Such applications carry health risks and should only be pursued under strict medical supervision.

Question 3: Is Ovidac safe for patients with a history of polycystic ovary syndrome (PCOS)?
Answer: Women with PCOS can use Ovidac when part of a controlled ovarian stimulation regimen, but clinicians must monitor for an exaggerated response that could precipitate OHSS. Dose adjustments and close laboratory follow‑up are essential.

Question 4: What laboratory tests are required during treatment?
Answer: Typical monitoring includes serum estradiol on the day of HCG administration, testosterone levels in men before and after therapy, and a pregnancy test for women of childbearing potential to confirm non‑pregnancy status prior to dosing.

Question 5: Where can I verify the authenticity of Ovidac 10,000 IU purchased online?
Answer: Purchase only from licensed pharmacies or authorized distributors. Verify the manufacturer’s label, batch number, and expiration date, and consider checking the MedlinePlus drug entry for additional safety information.